(WFRF:(Parekh N))
Search: (WFRF:(Parekh N)) > (2011-2014) > Trabectedin plus pe...
- 1 of 3
- Previous record
- Next record
- To hitlist
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
- Kaye, S. B. (author)
- Colombo, N. (author)
- Monk, B. J. (author)
- show more...
- Tjulandin, S. (author)
- Kong, B. (author)
- Roy, M. (author)
- Chan, S. (author)
- Filipczyk-Cisarz, E. (author)
- Vergote, I. (author)
- Lebedinsky, C. (author)
- Parekh, T. (author)
- Santabarbara, P. (author)
- Park, Y. C. (author)
- Nieto, A. (author)
- Poveda, A. (author)
- show less...
- (creator_code:org_t)
- Elsevier BV, 2011
- 2011
- English.
- In: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 22:1, s. 49-58
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L. P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian cancer, particularly in the partially platinum-sensitive subgroup [platinum-free interval (PFI) of 6-12 months]. This superiority has been suggested to be due to the differential impact of subsequent (platinum) therapy. Patients and methods: A detailed analysis of subsequent therapies and survival outcomes in the overall population and in the subsets according to platinum sensitivity was therefore conducted. Results: Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), including further platinum-based regimens (49% versus 55%). Patients in the trabectedin/PLD arm received subsequent chemotherapy at a later time (median delay 2.5 months versus PLD arm). Overall survival from subsequent platinum was significantly prolonged in the partially platinum-sensitive disease subset (hazard ratio = 0.63; P = 0.0357). Conclusion: The superiority of trabectedin/PLD over single-agent PLD in OVA-301 cannot be explained by differences in the extent or nature of subsequent therapies administered to these patients. On the other hand, these exploratory analyses support the hypothesis that the enhanced survival benefits in the partially platinum-sensitive subset might be due to an extended PFI leading to longer survival with subsequent platinum.
Keyword
- pegylated liposomal doxorubicin
- platinum-free interval
- relapsed ovarian cancer
- trabectedin
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Annals of Oncology (Search for host publication in LIBRIS)
To the university's database
- 1 of 3
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Kaye, S. B.
- Colombo, N.
- Monk, B. J.
- Tjulandin, S.
- Kong, B.
- Roy, M.
- show more...
- Chan, S.
- Filipczyk-Cisarz ...
- Hagberg, Hans
- Vergote, I.
- Lebedinsky, C.
- Parekh, T.
- Santabarbara, P.
- Park, Y. C.
- Nieto, A.
- Poveda, A.
- show less...
- Articles in the publication
- Annals of Oncolo ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
